Cupid Ltd

- There is no mention of any current or planned fundraising through debt or equity in the Q3 FY22 earnings call transcript. - The company has about ₹72 crores in cash including mutual funds, FDs, and bank balances. - The board is considering a share buyback program but is also evaluating working capital needs for the IVD division before making a final decision. - Capital expenditure for the new IVD division is mostly complete with around ₹10 crores spent. - No new funding plans through issuance of equity or debt have been disclosed.

- Cupid Limited has completed its new manufacturing facility at Nasik, with regulatory approvals (ICMR and Drug Controller of India) expected by end of March 2022. - The Nasik facility focuses on manufacturing 9 products including male condoms, female condoms, lubricant jelly, and IVD products. - Capital expenditure (CAPEX) for the IVD division is mostly complete, with about ₹8 crore spent and an additional ₹2 crore anticipated, totaling ₹10 crore. - No current or future large CAPEX beyond this has been specified; the company is cautious with working capital requirements for the IVD business. - The management is considering strategic options like a share buyback but is awaiting clearer working capital estimates for the IVD segment before final decisions.

- Cupid Limited projects a top-line revenue of about Rs. 170 crore for FY23, showing recovery and growth from FY22 levels. - Female condom sales are expected to increase significantly, contributing to higher margins and overall profitability. - The company aims for a profit after tax of at least Rs. 20 crore in FY23, an improvement over the Rs. 16-17 crore expected in FY22. - New manufacturing facility at Nasik expected to start commercial production by April 2022, producing about 9 products including male condoms, female condoms, lubricant jelly, and IVD products. - Capacity utilization for male condoms is near 98-100%, indicating strong demand. - The company expects gradual growth in the IVD business after regulatory approvals, though precise volume forecasts are yet uncertain. - South African government orders (approx. Rs. 100 crore annually) and tender wins in Tanzania (Rs. 75 crore) are expected to drive volume growth. - Emphasis on high-margin products and exports for sustained revenue improvement.

- FY22 projected net profit is around ₹16-17 crore, with Q3 net profit at ₹13 crore (Page 11). - FY23 guidance projects top line (revenue) around ₹170 crore and a minimum PAT (profit after tax) of ₹20 crore (Pages 6, 14). - FY23 profit outlook considers a gradual increase in female condom sales, which are high-margin products, helping improve the bottom line (Pages 5, 11, 14). - Operating profits likely to be lower than FY20 due to product mix changes and higher input costs but expected to improve in FY23 (Pages 5, 14). - EPS growth expected moderately post share buyback (under consideration) which may improve EPS despite flat absolute profits (Page 6). - IVD business expected to break even starting FY23, with commercial production beginning April 2022 (Pages 7, 8). Overall, cautious optimism on earnings improvement with focus on high-margin products and new facility utilization.

- Current order book is ₹141 crore, which includes the ₹100 crore annual order from South African government. - The South African order is for three years, extending up to January 2025. - Out of this ₹100 crore order, ₹70 crore is for female condoms. - Additional orders include about ₹30 to 40 crore expected from UNFPA, split roughly 60% male condoms and 30-40% female condoms, timings and quantities vary. - Tanzania tender order expected to be about ₹75 crore, with final decision in March. - Brazil tender expected around April 2022, but final quantities unclear due to national elections. - No confirmed orders yet for IVD business as manufacturing licenses are pending approval. - Management expects gradual increase in order book and sales in FY22 and FY23, especially with the new Nasik facility becoming operational.